Xuan Dung Pham

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Household Financial Burden and Poverty Impacts of Cancer Treatment in Vietnam

Hoàng Văn Minh, Cẩm Phương Phạm, Vu Quynh et al. · BioMed Research International · 2017 · 64 citations · Full text

Protocol for the ROSE sustainment (ROSES) study, a sequential multiple assignment randomized trial to determine the minimum necessary intervention to maintain a postpartum depression prevention program in prenatal clinics serving low-income women

Jennifer E. Johnson, Shannon Wiltsey Stirman, Alla Sikorskii et al. · Implementation Science · 2018 · 45 citations · Full text

Pathogenic Variant Profile of Hereditary Cancer Syndromes in a Vietnamese Cohort

Van Thuan Tran, Sao Trung Nguyen, Xuan Dung Pham et al. · Frontiers in Oncology · 2022 · 22 citations · Full text

4O First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes

Natalia Valdiviezo, Isamu Okamoto, Brett Hughes et al. · ESMO Open · 2024 · 22 citations · Full text

Neuro-oncology, Tsst Hr, Health Sciences +14